Business
Femasys Inc. Announces Financial Results for the Year Ended December 31, 2021
-- Company builds out management team and continues to implement its clinical programs to advance much-needed technologies for women’s health -- ATLANTA,
About this update from Femasys Inc.
[{"type":"text","content":"-- Company builds out management team and continues to implement its clinical programs to advance much-needed technologies for women’s health -- ATLANTA, March 24, 2022 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health, today announced financial results for the year ended December 31, 2021. “We are entering this year as a stronger public company with solid leadership, after strengthening both our management team as well as our board,” said Kathy Lee-Sepsick, founder, president and chief executive officer of Femasys. “We are advancing our product candidates to address various underserved areas of women’s reproductive health by implementing our clinical programs - addressing infertility and permanent birth control. We continue to support commercial efforts for our diagnostic product FemVue®, the first in-office alternative for ultrasound diagnosis of fallopian tubes for infertility. Commercial launch is pending later this year for our diagnostic product, FemCerv®, a biopsy tool used to diagnose cervical cancer by sampling cervical tissue, to address yet another underserved area of the gynecologic market. We are committed to designing solutions to improve the continuum of healthcare options for women, with the goal to further grow each of these substantial, multi-billion-dollar global market segments.” 2021 and Recent Corporate Highlights Operational and Leadership Dov Elefant was appointed to chief financial officer (CFO). Mr. Elefant has 25 years of financial management experience at both public and private biopharmaceutical companies. Mr. Elefant brings a proven record as a senior level global financial expert with financial reporting, fundraising, and mergers and acquisitions expertise. Wendy Perrow joined as a new board member. Ms. Perrow brings decades of experience in the life sciences industry related to fundraising, global product launches and corporate strategy. Edward G. Evantash, M.D., was appointed to chief medical officer (CMO). Dr. Evantash brings over two decades of industry experience in medical and clinical affairs, having previously served as CMO to Alydia Health and vice president of medical affairs at Hologic, Inc., both medical te...